Search - tctmd.com

Displaying 81 - 100 of 186

Sort: Relevancy | Date

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

TCTMD’s Top 10 Most Popular Stories for March 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2018

April 02, 2018

‘Practical Guide’ for NOACs Gets an Update

News Daily News

‘Practical Guide’ for NOACs Gets an Update

March 20, 2018

No Increased Risk of Serious Liver Injury Seen With NOACs

News Daily News

No Increased Risk of Serious Liver Injury Seen With NOACs

March 13, 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

News Conference News ACC 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

March 13, 2018

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

News Conference News ACC 2018

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

March 12, 2018

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing PCI: "Dual Therapy is the right choice”

Presentation JIM 2018

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing PCI: "Dual Therapy is the right choice”

Presenter: Roxana Mehran

February 23, 2018

Could NOACs Have a Role for Secondary Prevention After STEMI?

News Daily News

Could NOACs Have a Role for Secondary Prevention After STEMI?

February 08, 2018

News Industry News

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

January 29, 2018

More Evidence Rivaroxaban May Carry Higher Bleeding Risk Than Other NOACs

News Conference News ISC 2018

More Evidence Rivaroxaban May Carry Higher Bleeding Risk Than Other NOACs

January 27, 2018

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

January 02, 2018

ACC Provides Guidance on How to Manage Bleeding in Patients Taking Oral Anticoagulants

News Daily News

ACC Provides Guidance on How to Manage Bleeding in Patients Taking Oral Anticoagulants

December 04, 2017

Nephroprotective NOACs? Renal Dysfunction Not Infrequent Among A-fib Patients, but Some Agents Reduce Risk

News Daily News

Nephroprotective NOACs? Renal Dysfunction Not Infrequent Among A-fib Patients, but Some Agents Reduce Risk

Yael L. Maxwell

November 28, 2017

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

News Conference News AHA 2017

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

November 22, 2017

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

News Conference News AHA 2017

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

November 15, 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

News Conference News AHA 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

November 09, 2017

Amulet: Data Synthesis and Ongoing Trials

Presentation TCT 2017

Amulet: Data Synthesis and Ongoing Trials

Presenter: William A. Gray, Vivek Y. Reddy, Fabian Nietlispach

October 30, 2017

WATCHMAN: Data Synthesis and Ongoing Trials

Presentation TCT 2017

WATCHMAN: Data Synthesis and Ongoing Trials

Presenter: William A. Gray, Vivek Y. Reddy

October 30, 2017

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Presentation TCT 2017

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, C. Michael Gibson

October 30, 2017

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Presentation TCT 2017

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, Kurt Huber

October 30, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.